LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Akcijų sąrašas・Innoviva Inc

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.37 -0.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.27

Max

21.66

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-55M 187M
Pardavimai	-20M 98M
P/E Sektoriaus vid.	3.436 49.888
Pelnas, tenkantis vienai akcijai	0.47
Pelno marža	190.415
Darbuotojai	159
EBITDA	-160M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+60.39% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-115M 1.6B
Ankstesnė atidarymo kaina	21.74
Ankstesnė uždarymo kaina	21.37

Naujienos nuotaikos

By Acuity

20%

80%

42 / 344 reitingas Healthcare

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-02 20:30; UTC

Uždarbis

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026-06-02 23:58; UTC

Rinkos pokalbiai

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026-06-02 23:41; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026-06-02 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026-06-02 22:57; UTC

Rinkos pokalbiai

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026-06-02 22:50; UTC

Rinkos pokalbiai

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026-06-02 21:00; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-02 20:46; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:38; UTC

Uždarbis

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026-06-02 20:21; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:12; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Product Rev $594M

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Loss $177M >PANW

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

60.39% į viršų

12 mėnesių prognozė

Vidutinis 34.5 USD 60.39%

Aukščiausias 46 USD

Žemiausias 18 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Innoviva Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

42 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.